Comprehensive review into the challenges of gastrointestinal tumors in the Gulf and Levant countries

Figure 1 Five-year recurrence-free survival and overall survival. A: Five-year recurrence-free survival and overall survival at a median follow-up of 54 mo with 3-year vs 1-year imatinib adjuvant treatment in patients with resected gastrointestinal stromal tumors estimated to be at high risk of recurrence[39]. B: Five-year recurrence-free survival and overall survival at a median follow-up of 90 mo with 3-year vs 1-year imatinib adjuvant treatment in patients with resected gastrointestinal stromal tumors estimated to be at high risk of recurrence[40]. OS: Overall survival; RFS: Recurrence-free survival.

Figure 2 Algorithm for the management of localized primary gastrointestinal stromal tumors. CT: Computed tomography; GI: Gastrointestinal; GIST: Gastrointestinal stromal tumors; MRI: Magnetic resonance imaging; R0: No residual tumor; R1: Microscopic residual tumor.